Biopharmacy and Biomedicine Market to Pass US $ 800.0 Billion Threshold by 2027 | Future opportunities from the best players F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc.

Global Biopharmaceuticals and Biomedicine Market – Overview

Biopharmaceuticals are drugs that are produced using biotechnology and biological sources. Biopharmaceuticals contain a number of products such as monoclonal antibodies, vaccines, recombinant human insulin, human growth hormone, erythropoietin, interferon, colony stimulating factor and blood factors. Currently, biopharmaceuticals represent more than a fifth of the pharmaceutical market, and this percentage share of biopharmaceuticals is expected to increase, due to its advantage over fully synthesized pharmaceutical drugs. Fewer side effects, high efficacy and potent action, and the ability to cure disease rather than treat it are some of the main benefits of these drugs.

Get Sample Report With Latest Information @

Market dynamics – Engines

Rising Launches, Approvals and Strong Biopharmaceuticals Pipeline Expected to Drive Market Growth

The increasing launch, approvals of new biopharmaceuticals and the strong pipeline of such products are expected to boost the global biopharmaceutical and biomedical market during the forecast period. In the recent past, regulators in key regions such as the United States and Europe have approved a number of biopharmaceuticals, which have subsequently been released to the market. For example, in 2017, Johnson & Johnson received US Food and Drugs Administration (FDA) approval for its new immunology product, Tremfya (Guselkumab), used for the treatment of moderate-to-moderate plaque psoriasis. severe. In 2017, Sanofi SA received US FDA approval for its new Admelog, a fast-acting insulin indicated for the management of blood sugar at mealtime. In 2017, the US FDA approved the new Shingrix from GlaxoSmithKline Plc., A shingles vaccine. The US FDA has approved this vaccine for use by people aged 50 and over as immunization against painful disease caused by latent chickenpox infection. In 2017, Spark Therapeutics, Inc. received US FDA approval for its LUXTURNA (voretigene neparvovec-rzyl). LUXTURNA is the first gene therapy and pharmacological treatment for inherited retinal disease (IRD) and the first adeno-associated virus (AAV) vector gene therapy approved in the United States. In 2017, HumanZyme Inc. launched its new HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is a type I family interferon, which activates innate Th1-type immune responses against viral and bacterial infections. In 2016, Novo Nordisk A / S launched its new once-daily basal insulin Tresiba (insulin degludec) in the US market and in 2017, Nordisk A / S received approval from the China Food and Drug Administration (CFDA) to market his Tresiba. (insulin degludec) in China. Thus, frequent product approvals and launches are expected to propel the global market biopharmaceuticals and biomedicines market growth during the forecast period.

The global biopharmaceutical and biomedicine market was valued at US $ 358.4 billion in 2016 and is expected to experience a CAGR of 9.4% during the forecast period (2017-2025).

The increase in strategic acquisitions and collaboration of major players is expected to drive the market growth in the near future.

Major market players are involved in various growth strategies such as collaborations and acquisitions which in turn are expected to fuel the market growth in the near future. For example, in February 2018, LGC Limited, a UK-based company, acquired Lucigen Corporation, a US developer and manufacturer of enzymes, reagents and molecular biology kits. Through this strategic acquisition, LGC Limited has expanded its portfolio with Lucigen’s broad portfolio of NGS kits, enzymes, competent cells and cloning systems. In February 2018, Laboratoires Servier and ImmunoQure AG entered into a strategic collaboration for the development of a therapeutic autoantibody neutralizing interferon-a. In March 2018, Wuxi Biologics Co. Ltd. collaborated with Adagene Inc. for the discovery and development of novel therapeutic antibodies. In 2017, Omicia, Inc., acquired a bioinformatics startup Spiral Genetics for an undisclosed amount. With this acquisition of Spiral’s advanced tools, Omicia, Inc., has broadened its portfolio of bioinformatics tools and strengthened its position in the global market.

Get PDF Brochure With Latest Information @

In addition, increased funding and investment to support the development and research of new biopharmaceuticals is also expected to drive the growth of the market. For example, in 2017, the Indian government launched a national biopharmaceutical mission. In accordance with the program, the government invested US $ 250 million, including a loan of US $ 125 million from the World Bank to promote the development of biological drugs in India. In 2017, the University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) collaborated on the development of new nanomedicine approaches for the treatment of HIV and received a $ 3 million award from the National Institutes of Health (NIH ) to generate new technologies and pursue research and development.

Market dynamics – Constraints

The cost of biopharmaceuticals and biomedicals is quite high because they require a research and development process. In addition, their manufacturing process is too complex, which requires skilled scientists. Such expensive biopharmaceuticals are not affordable for organizations in emerging economies such as India, China and Africa. The high cost of biopharmaceutical and biomedical products is a major factor hindering its adoption. For example, in India, a vial of Avastin, a monoclonal antibody, costs between US $ 372.65 and US $ 402.46. The cost of gene therapy such as Kymriah is very high. Kymriah is an autologous genetically modified T-cell immunotherapy directed against CD19, indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia. The cost of Kymriah cancer treatment from Novartis AG is approximately 475 years. US $ 000. Thus, the high cost associated with biopharmaceuticals is expected to restrain the growth of the global biopharmaceutical and biomedical products market in the near future.

Key points of the Biopharmaceuticals and Biomedicine market:

  • The global biopharmaceutical and biomedicine market is expected to grow at a CAGR of 9.4% during the forecast period (2017-2025) owing to the increasing development of new technologies and strategic collaboration among major players.
  • North America was the dominant region in the global biopharmaceutical and biomedicine market and is expected to maintain its dominance during the forecast period (2017-2025). This is due to the presence of major key players and increased funding by various organizations to support biopharmaceutical research. For example, in 2015, the National Institutes of Health (NIH) funded US $ 54 million to support emerging challenges in biomedical research. The NIH has funded the launch of four major science programs, namely the Glycoscience Program, the 4D Nucleome Program, the Gabriella Miller Kids First Research Program, and the Science of Behavior Change Program.
  • Asia-Pacific is expected to show the highest growth and register a CAGR of 15.3% during the forecast period due to increased research and development activity in China. For example, in 2016, researchers at Sichuan University in Chengdu inserted reconfigured cells into a lung cancer patient who was participating in a clinical trial at West China Hospital.
  • The main players operating in the biopharmaceutical and biomedicine market are Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi SA, Eli Lilly and Company, AbbVie Inc. , Novo Nordisk A / S, Bristol – Myers Squibb, NanoString Technologies, Inc., Qiagen NV, Celgene Corporation and Affimed NV

Purchase this premium report here to access all information @

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, custom research solutions, and advisory services.


Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837

About Norman Griggs

Check Also

A Dangerous X-Men Ally Is Secretly One Of Their Diabolical Villains

The X-Men will have a hard time coming to terms with the revelation that one …

Leave a Reply

Your email address will not be published.